Resource Hub

What reputational risks are on the horizon and what should companies do now?

Topic : News and Press Type : Briefing

This article is brought to you by ABHI member, Alder

Authored by Jack Myers, Associate Director, Alder

HealthTech companies face particular reputational pressures: products and services can directly affect patient care, their customers are often publicly funded, and a problem with a device or digital system can quickly attract national scrutiny. As technology advances, regulation tightens and NHS expectations change, companies are having to prepare for reputational risks that may not have featured prominently on their radar a few years ago.

Despite this, our latest research suggests many companies are less prepared than their leaders believe.

The distance trap

In August 2026, Alder commissioned Censuswide to survey 250 UK senior decision-makers with responsibility for risk across a range of sectors. Life sciences leaders were the most confident of any sector, with almost three-quarters (74%) very confident their organisation would respond effectively to a major reputational incident. They were also the most likely to have a crisis communications plan (28%, against 20% across all sectors). Yet only 8% monitor how their stakeholders perceive them, the lowest of any sector.

We also asked respondents about ten common measures for managing reputational risk, including crisis communications plans, board-level escalation processes, stakeholder mapping, scenario exercises and spokesperson training. On average, organisations in health and life sciences had fewer than two mitigation measures in place.

The gap between how confident leaders are in their crisis preparation and their knowledge of what is actually in place is quite large; indeed, there is an emerging distance trap where the less a leader knows about their preparation, the more confident they are in their ability to weather a crisis. 

Emerging reputational risks

Given this, it is important to be clear-eyed about emerging reputational risk trends. A strong trend over the past twelve months has been cyber disruption, not just by hostile actors but also disruption caused by poorly-planned implementation or failure to risk-assess. 

Rapid AI adoption

AI is increasingly being used in diagnostics, triage, administration and patient communication, but public confidence has yet to catch up with its adoption. The Health Foundation's 2025 survey found that 80% of NHS staff supported AI in patient care, compared with 54% of the public.

The reputational consequences of getting implementation wrong are already apparent. In August, complaints that an AI receptionist in Rotherham struggled to understand patients' Yorkshire accents attracted national coverage, raising questions about accessibility and the potential for patients to be excluded from services.

AI is also a concern for life sciences leaders in our research. Over a quarter (28%) identified AI-driven mistakes or bias in their systems becoming public as a reputational risk, the highest proportion of any sector. Incorrect information generated about their organisation by AI tools, and sensitive data being exposed through AI tools, followed at 24% each.

Deepfakes and misinformation

The BMJ has documented deepfake videos of well-known UK doctors apparently endorsing health products, including purported treatments for serious medical conditions.

As these tools become more convincing, HealthTech companies face the prospect of fake endorsements, fabricated safety claims, impersonation of senior executives and misinformation about their products spreading before the facts can be established.

Cyber risk extending through the supply chain

The 2024 ransomware attack on a pathology services provider to London hospitals, demonstrated how a supplier falling victim to a cyber-attack can have serious consequences for patient care. The attack disrupted blood testing and led to the postponement of thousands of appointments and procedures.

Cyber resilience is also receiving greater attention from policymakers and NHS buyers, and companies are increasingly finding themselves having to mop up collateral reputational damage caused by negligence somewhere in their supply chain. 

Where are companies planning to invest?

Companies appear to recognise some of these gaps. Asked which area would receive the most investment over the next two years, the most common answer across our survey was stakeholder engagement and perception research (20%), followed by training (15%) and crisis planning and response capability (14%). The challenge, of course, will be turning those intentions into meaningful preparation.

What should companies do now?

  • Make horizon scanning routine. Review emerging reputational risks regularly with a formal board-level discussion at least annually. 
  • Know your own AI. Map where AI is being used, including employees' use of publicly available tools. Understand what each system can do, its limitations and who is responsible for checking its outputs. Be prepared to explain these arrangements in plain English.
  • Test your plans against emerging scenarios. A cyber-attack on a hosted service, a serious medical device incident requiring notification to the MHRA or a deepfake of your chief executive are all plausible scenarios. Exercises should test how decisions are made and how communications are coordinated with customers, regulators and other stakeholders.
  • Agree who decides. Establish clear escalation arrangements, including when an issue reaches the board and who is responsible for approving regulatory notifications, customer communications and public statements. These processes need to work under pressure and within regulatory deadlines.
  • Prepare your spokespeople. Senior leaders should be comfortable explaining technical issues to non-specialist audiences, particularly when patient safety is involved. Clinicians, NHS customers and the public will expect clear answers about the implications for care and what the company is doing in response.

Ultimately, companies should be able to demonstrate their preparedness, whether to their boards, customers, regulators or investors. That means having evidence of the risks they have considered, the arrangements they have put in place and how those arrangements have been tested.

Confidence matters in a crisis, but it is worth far more when supported by preparation that can withstand scrutiny.

Alder is a reputation, risk and crisis advisory firm. Key findings from its 2026 research are available at alder-uk.com/distance-trap-research